Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation

Table 1 Comparison of demographic and clinicopathological data of patients with hepatocellular carcinoma classified by different neutrophil-lymphocyte ratios

Variable	NLR < 3 (n = 105)	3 ≤NLR < 4 (n = 61)	4 ≤NLR < 5 (n = 56)	NLR≥5 (n = 58)	P (2-tailed)
Gender (F/M)	16/89	4/57	7/49	4/54	0.235
Age, yr (mean)	47.0	46.4	45.6	46.8	0.529
Age, yr (≥ 60/< 60)	13/92	5/56	6/50	7/51	0.859
Child-Pugh class (A/B/C)	59/39/7	31/26/4	31/21/4	25/22/11	0.083
BMI (mean)	23.3	22.3	22.2	22.9	0.899
AFP, g/L (< 400/≥ 400)	53/52	30/31	19/37	31/27	0.145
Preoperative adjuvant therapy (Y/N)	47/58	27/34	22/34	31/27	0.492
Tumor ( ≤ 3/> 3), n	90/15	49/12	41/15	39/19	0.0362
Largest tumor size, cm ( ≤ 5/5-9/> 9)	50/32/23	29/17/15	20/19/17	21/14/23	0.168
Total tumor size, cm ( ≤ 5/5-9/> 9)	41/31/33	24/16/21	13/17/26	15/10/33	0.257
Macro-vascular invasion (Y/N)	20/85	13/48	20/36	21/37	0.0282
Micro-vascular invasion (Y/N)	44/61	28/33	33/23	35/23	0.059
Differentiation (1-2/3-4)	44/171	26/141	29/151	32/151	0.866
HBV infection (-/+)	5/100	3/58	1/55	8/50	0.064
Donor (living/deceased)	30/75	13/48	16/40	7/51	0.083

¹Differentiation was reported for 192 patients;

²Significant P value. NLR: Neutrophil-lymphocyte ratios; BMI: Body mass index; AFP: α-fetoprotein; HBV: Hepatitis B virus.